SG11201906781VA - Antimicrobial compositions comprising copper-hydroxypyrone complexes - Google Patents
Antimicrobial compositions comprising copper-hydroxypyrone complexesInfo
- Publication number
- SG11201906781VA SG11201906781VA SG11201906781VA SG11201906781VA SG11201906781VA SG 11201906781V A SG11201906781V A SG 11201906781VA SG 11201906781V A SG11201906781V A SG 11201906781VA SG 11201906781V A SG11201906781V A SG 11201906781VA SG 11201906781V A SG11201906781V A SG 11201906781VA
- Authority
- SG
- Singapore
- Prior art keywords
- copper
- international
- complexes
- pct
- peg
- Prior art date
Links
- PFPGISXUTIURGU-UHFFFAOYSA-N OC=1C(OC=CC1)=O.[Cu] Chemical class OC=1C(OC=CC1)=O.[Cu] PFPGISXUTIURGU-UHFFFAOYSA-N 0.000 title abstract 3
- 230000000845 anti-microbial effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 4
- 229910052802 copper Inorganic materials 0.000 abstract 4
- 239000010949 copper Substances 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 abstract 2
- 239000002674 ointment Substances 0.000 abstract 2
- LIPRKYKMVQPYPG-UHFFFAOYSA-N 3-Hydroxy-2H-pyran-2-one Chemical class OC1=CC=COC1=O LIPRKYKMVQPYPG-UHFFFAOYSA-N 0.000 abstract 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000003385 bacteriostatic effect Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 150000001879 copper Chemical class 0.000 abstract 1
- 229940043353 maltol Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1701944.9A GB201701944D0 (en) | 2017-02-06 | 2017-02-06 | Antimicrobial compositions and their uses |
| PCT/EP2018/052958 WO2018141989A1 (en) | 2017-02-06 | 2018-02-06 | Antimicrobial compositions comprising copper-hydroxypyrone complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906781VA true SG11201906781VA (en) | 2019-08-27 |
Family
ID=58462497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906781VA SG11201906781VA (en) | 2017-02-06 | 2018-02-06 | Antimicrobial compositions comprising copper-hydroxypyrone complexes |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11000502B2 (https=) |
| EP (1) | EP3576730A1 (https=) |
| JP (1) | JP2020506201A (https=) |
| CN (1) | CN110248654A (https=) |
| AU (1) | AU2018216241A1 (https=) |
| BR (1) | BR112019016189A2 (https=) |
| CA (1) | CA3051519A1 (https=) |
| GB (1) | GB201701944D0 (https=) |
| SG (1) | SG11201906781VA (https=) |
| WO (1) | WO2018141989A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220175602A1 (en) * | 2019-12-02 | 2022-06-09 | Halcyon Inc. | Bedsore-preventing mattress combined with sound vibration module and air fibers, and operating method therefor |
| CN111647533A (zh) * | 2020-06-16 | 2020-09-11 | 科里思特(福建)生物科技有限公司 | 一种枯草芽孢杆菌及其制剂与应用 |
| JP2024074602A (ja) * | 2022-11-21 | 2024-05-31 | エステー株式会社 | 抗菌剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138155A (ja) * | 1993-11-12 | 1995-05-30 | Otsuka Pharmaceut Co Ltd | 抗微生物剤 |
| GB9621273D0 (en) * | 1996-10-11 | 1996-11-27 | Cortecs Ltd | Therapeutic method |
| HUP0103667A3 (en) * | 1998-09-23 | 2007-10-29 | Unilever Nv | Oral care compositions and use of metal complexes for producing of such compositions |
| US6505233B1 (en) | 1999-08-30 | 2003-01-07 | Zaplet, Inc. | Method for communicating information among a group of participants |
| JP2002255956A (ja) * | 2001-02-27 | 2002-09-11 | Sumitomo Chem Co Ltd | 防カビ剤 |
| JP2009256228A (ja) * | 2008-04-15 | 2009-11-05 | Lion Corp | 液体口腔用組成物 |
| GB201402672D0 (en) * | 2014-02-14 | 2014-04-02 | Medical Res Council | Materials and methods relating to stabilised polymeric silicate compositions |
-
2017
- 2017-02-06 GB GBGB1701944.9A patent/GB201701944D0/en not_active Ceased
-
2018
- 2018-02-06 CN CN201880010474.0A patent/CN110248654A/zh active Pending
- 2018-02-06 AU AU2018216241A patent/AU2018216241A1/en not_active Abandoned
- 2018-02-06 BR BR112019016189A patent/BR112019016189A2/pt not_active Application Discontinuation
- 2018-02-06 CA CA3051519A patent/CA3051519A1/en not_active Abandoned
- 2018-02-06 SG SG11201906781VA patent/SG11201906781VA/en unknown
- 2018-02-06 JP JP2019542542A patent/JP2020506201A/ja active Pending
- 2018-02-06 EP EP18704508.3A patent/EP3576730A1/en not_active Withdrawn
- 2018-02-06 US US16/480,363 patent/US11000502B2/en not_active Expired - Fee Related
- 2018-02-06 WO PCT/EP2018/052958 patent/WO2018141989A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020506201A (ja) | 2020-02-27 |
| CN110248654A (zh) | 2019-09-17 |
| EP3576730A1 (en) | 2019-12-11 |
| US11000502B2 (en) | 2021-05-11 |
| WO2018141989A1 (en) | 2018-08-09 |
| CA3051519A1 (en) | 2018-08-09 |
| BR112019016189A2 (pt) | 2020-04-14 |
| US20190380996A1 (en) | 2019-12-19 |
| AU2018216241A1 (en) | 2019-08-29 |
| GB201701944D0 (en) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201908171TA (en) | Compounds and compositions for treating hematological disorders | |
| SG11201906534XA (en) | Antifouling composition | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201408605UA (en) | Methods for biodegradable derivatization of cellulosic surfaces | |
| SG11201808625QA (en) | SOLUBLE C5aR ANTAGONISTS | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201809976PA (en) | Protection of plant extracts and compounds from degradation | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
| SG11201811579VA (en) | Chemiluminescent substrates | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201407812SA (en) | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201810192TA (en) | Antibacterial compositions | |
| SG11201907948TA (en) | Formulations comprising pd-1 binding proteins and methods of making thereof | |
| SG11201900883UA (en) | Combination treatment for hematological cancers | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201906781VA (en) | Antimicrobial compositions comprising copper-hydroxypyrone complexes | |
| SG11201810428PA (en) | Composition and methods for microbiota therapy | |
| SG11201811341QA (en) | Sugar composition | |
| SG11201811788SA (en) | Antibodies with low immunogenicity and uses thereof | |
| SG11201901129XA (en) | Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy | |
| SG11201809031XA (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |